Residency · Residency · Dermatology

Vitiligo: Pathogenesis and Repigmentation Strategies

Introduction

Vitiligo is a chronic autoimmune depigmenting disorder affecting approximately 0.5-2% of the global population. The disease results from progressive loss of epidermal melanocytes, creating disfiguring depigmented patches that profoundly affect quality of life, particularly in individuals with darker skin tones. Recent advances in understanding the immune pathogenesis of vitiligo have led to breakthrough targeted therapies, most notably topical JAK inhibitors.

Epidemiology

The worldwide prevalence of vitiligo is 0.5 to 2%, with no significant racial or sex predilection. Fifty percent of patients present before age 20, though it can occur at any age. Family history is positive in 15 to 20% of patients, and first-degree relatives carry a 5 to 8% risk. Associated autoimmune conditions include autoimmune thyroid disease (the most common association, affecting 15 to 25%), type 1 diabetes, pernicious anemia, Addison disease, alopecia areata, and rheumatoid arthritis.

Pathogenesis

Convergence Theory

Multiple pathogenic mechanisms converge to cause melanocyte destruction.

Autoimmune Hypothesis (Primary Mechanism)

CD8+ cytotoxic T cells targeting melanocyte antigens are the principal effectors. The melanocyte-specific antigens include tyrosinase, Melan-A/MART-1, gp100/Pmel17, TRP-1, and TRP-2. IFN-gamma is the dominant cytokine, produced by CD8+ T cells and signaling through the JAK1/JAK2-STAT1 pathway in keratinocytes. IFN-gamma induces keratinocyte production of CXCL9 and CXCL10 (CXCR3 ligands), which recruit additional CD8+ T cells to the skin, creating a positive feedback loop identical to the mechanism in alopecia areata. Regulatory T-cell (Treg) dysfunction allows unchecked effector T-cell activity. Resident memory T cells (TRM) at prior lesion sites maintain disease memory and drive relapse.

Oxidative Stress Hypothesis

Melanocytes in vitiligo patients have inherent defects in managing reactive oxygen species (ROS). Elevated hydrogen peroxide (H2O2) and decreased catalase in lesional skin damage melanocytes and trigger innate immune activation through the NLRP3 inflammasome and HMGB1 release.

Neural Hypothesis

The neural hypothesis explains the segmental variant, proposing that neuropeptide release (substance P, norepinephrine) may cause melanocyte damage along dermatomes. This is supported by the dermatomal distribution of segmental vitiligo.

Genetic Susceptibility

Vitiligo follows polygenic, multifactorial inheritance. GWAS have identified over 50 risk loci, predominantly involving immune regulation genes including **HLA-A02:01, PTPN22, NLRP1, CTLA4, and IL2RA*. Several vitiligo susceptibility genes overlap with other autoimmune diseases.

<image>Diagram of vitiligo immunopathogenesis showing: melanocyte stress and ROS generation activating the innate immune system, IFN-gamma production by CD8+ T cells signaling through JAK1/JAK2-STAT1 in keratinocytes, keratinocyte production of CXCL9/CXCL10 recruiting additional CXCR3+ T cells, and sites of therapeutic intervention including JAK inhibitor blockade and anti-IFN-gamma approaches</image>

Clinical Features

Non-Segmental Vitiligo (NSV)

Non-segmental vitiligo is the most common form (85 to 90%), presenting with bilateral, symmetric depigmented macules and patches. It has a predilection for periorificial areas (perioral, periorbital, perianal), acral sites (hands, feet, wrists), and areas of friction or trauma (Koebner phenomenon). The course is progressive with periods of stability and flare. Subtypes include focal, acrofacial, mucosal, generalized, and universal (above 80% BSA).

Segmental Vitiligo (SV)

Segmental vitiligo is unilateral, typically confined to a single dermatome or segment. It has an earlier onset (childhood), with rapid initial spread that then stabilizes within 1 to 2 years. It does not typically progress to non-segmental vitiligo, is less commonly associated with other autoimmune diseases, and responds poorly to medical therapy but well to surgical approaches.

Activity Assessment

Active disease indicators include confetti-like depigmentation at margins, trichrome vitiligo (three-color gradient), Koebner phenomenon, and inflammatory borders. Stable disease indicators include well-defined borders, no new lesions for more than 12 months, and repigmentation at margins. Wood's lamp examination enhances contrast of depigmented patches and is important for detecting early or subtle lesions in fair-skinned individuals.

Diagnosis

The diagnosis is clinical in most cases, based on acquired, chalk-white, depigmented macules and patches with characteristic distribution. Wood's lamp shows depigmented lesions fluorescing bright white, helping distinguish depigmentation from hypopigmentation (which does not enhance). Dermoscopy may reveal residual perifollicular pigmentation (indicating a melanocyte reservoir), a white glowing pattern, or a starburst pattern at active margins. Biopsy is rarely needed but shows absent or markedly reduced melanocytes with Fontana-Masson stain and a peribulbar lymphocytic infiltrate at the margins of active lesions.

Screening

TSH and anti-thyroid peroxidase (anti-TPO) antibodies should be checked at diagnosis and annually, as autoimmune thyroid disease is the most common association. CBC, fasting glucose, and vitamin B12 are checked if clinically indicated. ANA is not routinely recommended unless symptoms suggest lupus.

Treatment

Topical Therapies

Topical Corticosteroids

Topical corticosteroids are first-line for limited vitiligo (less than 10% BSA), using medium-to-high potency formulations (mometasone, betamethasone) applied daily for 3 to 6 months. Repigmentation occurs in 40 to 60% of patients, with best results on the face and trunk. Cycled application (2 weeks on, 2 weeks off) minimizes atrophy risk. Acral sites (hands, feet) respond less well.

Topical Calcineurin Inhibitors

Tacrolimus 0.1% or pimecrolimus 1% are preferred for the face, eyelids, and genital area where corticosteroid atrophy is a concern. They offer similar efficacy to potent TCS on the face but lower efficacy on the body. They can be used continuously without atrophy risk, and combination with NB-UVB enhances response.

Topical Ruxolitinib (JAK1/JAK2 Inhibitor)

Topical ruxolitinib is the first FDA-approved treatment specifically for vitiligo (Opzelura, ruxolitinib cream 1.5%), approved in July 2022 for NSV in patients aged 12 and older. It blocks the IFN-gamma-JAK1/JAK2-STAT1 signaling axis, suppressing CXCL9/CXCL10 production and CD8+ T-cell recruitment. The TRuE-V1 and TRuE-V2 trials showed that 30% of patients achieved 75% or greater improvement in Facial Vitiligo Area Scoring Index (F-VASI75) at 24 weeks versus 8 to 10% with placebo, with continued improvement through 52 weeks. It is applied twice daily to affected areas (up to 10% BSA) with a maximum of 60 g per week. Adverse effects include application-site acne (the most common), pruritus, and nasopharyngitis, with no significant systemic JAK inhibition at recommended doses. This agent represents a paradigm shift in vitiligo management.

Phototherapy

Narrowband UVB (NB-UVB)

NB-UVB is the gold standard for widespread vitiligo (above 10% BSA) and is also effective for limited disease. It stimulates melanocyte migration from the hair follicle reservoir, promotes melanocyte proliferation, and has immunomodulatory effects (inducing Tregs and suppressing CXCL10). Treatment involves 2 to 3 sessions per week, with initial response at 3 to 6 months, and should continue for at least 12 to 24 months. Response rates of 40 to 70% achieve greater than 50% repigmentation, with face and trunk responding best and acral areas being most resistant. Combination with topical agents (TCS, TCI, ruxolitinib) significantly enhances response. Home phototherapy units improve adherence and outcomes for long-term treatment.

Excimer Laser (308 nm)

The excimer laser provides targeted UVB therapy for localized vitiligo, delivering higher fluences to lesional skin while sparing normal surrounding skin. It is particularly useful for limited, stable patches.

Systemic Therapies

Oral mini-pulse corticosteroids (dexamethasone 2.5 mg on two consecutive days per week) stabilize progressive vitiligo but do not induce repigmentation. Oral JAK inhibitors (tofacitinib, baricitinib, ritlecitinib) are under investigation, showing efficacy in clinical reports but with common relapse upon discontinuation. Combination with phototherapy may be synergistic.

Surgical Therapies (for Stable Vitiligo)

Surgical therapies are indicated for stable disease (no progression for more than 12 months), failed medical therapy, or segmental vitiligo. Autologous melanocyte-keratinocyte transplant procedure (MKTP) involves harvesting cells from normal skin, processing them into a cell suspension, and applying them to a dermabraded recipient site, with excellent results in stable vitiligo. Suction blister epidermal grafting transfers donor epidermis to a recipient site after blister formation. Punch grafting is a simpler technique but may cause cobblestoning artifact. Surgical approaches are most effective for segmental vitiligo and stable focal patches.

Depigmentation (for Extensive Vitiligo)

Monobenzone 20% cream provides permanent depigmentation of remaining pigmented skin for patients with more than 50 to 80% BSA involvement who desire a uniform appearance. The process is irreversible and requires lifelong sun protection. Confetti-like depigmentation and contact sensitization may occur.

<image>Clinical before-and-after photographs showing vitiligo repigmentation patterns: perifollicular repigmentation (islands of pigment around hair follicles) after NB-UVB phototherapy, marginal repigmentation spreading from lesion borders after topical ruxolitinib, and diffuse repigmentation after combination therapy</image>

Quality of Life and Psychosocial Impact

Vitiligo significantly affects self-esteem, social functioning, and mental health. Higher rates of depression (10 to 25%), anxiety, and social avoidance are seen compared to the general population. The impact is greatest in patients with darker skin tones and in cultures where skin appearance carries social significance. Cosmetic camouflage products (Covermark, Dermablend) provide immediate improvement in quality of life. Clinicians should screen for psychological comorbidities at each visit and refer for counseling when appropriate.

Key Clinical Pearls

The IFN-gamma-CXCL10-CXCR3 axis is the central immune pathway driving vitiligo, and topical ruxolitinib directly blocks this pathway, representing the first mechanism-based therapy. Perifollicular repigmentation (pigment islands around hair follicles) indicates an intact melanocyte stem cell reservoir and predicts good treatment response. Leukotrichia (white hairs within vitiligo patches) indicates loss of the follicular melanocyte reservoir and predicts poor response to medical therapy, making surgical approaches more appropriate. All vitiligo patients should be screened for thyroid disease at diagnosis and annually. Combination therapy (topical JAK inhibitor plus phototherapy) produces superior results to either modality alone.

References

1. Harris JE, Harris TH, Weninger W, et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8+ T-cell accumulation in the skin. J Invest Dermatol. 2012;132(7):1869-1876.
2. Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445-1455.
3. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84.
4. Rodrigues M, Ezzedine K, Hamzavi I, et al. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017;77(1):1-13.

Read this lecture as Markdown